| Editor's Note: Fierce Biotech will not publish on Monday, May 29, due to the Memorial Day holiday. We'll be back in your inboxes on Tuesday, May 30. Enjoy your long weekend! |
|
Cell and gene therapies for rare diseases often present unique obstacles that can be overcome using in silico approaches. Learn how in our on-demand webinar, and meet us at BIO to discuss how Premier Consulting can advance your CGT program to its next milestone. Premier Consulting. Built for Biotech℠.
|
|
Today's Big NewsMay 26, 2023 |
|
July 18-19, 2023 | Jersey City, NJ
More panels and case studies providing real, practical experiences and solutions, including topics surrounding Investor Relations and Government Affairs. Save $500 when you Register before May 30th!
|
|
| By James Waldron Roche's faith in TIGIT may have finally been rewarded, as tiragolumab shows signs of efficacy in liver cancer. |
|
|
|
By Gabrielle Masson Regeneron believes its LAG-3 inhibitor and PD-1 inhibitor combo for patients with advanced melanoma could serve as a rival to Bristol Myer Squibb’s Opdualag, although a significant portion of patients discontinued treatment in a phase 1 study. |
By James Waldron A year after getting Pfizer’s backing, Zentalis Pharmaceuticals says new data for a WEE1 candidate justifies putting the asset into a phase 3 study for ovarian cancer next year. |
By Helen Floersh After a motorbike accident left him paralyzed from the waist down, Gert-Jan wished to walk again. Now, with the help of a "digital bridge" that connects his brain to his spinal cord, he can. |
|
Explore the whole transcriptome with a prep that generates libraries in under 4.5 hours - including rRNA depletion - and delivers superior gene detection sensitivity with FFPE and low inputs. View the Data.
|
|
By James Waldron The U.K. government has pledged that a chunk of the 650 million pound sterling ($803 million) funding package assigned to boost the country’s life sciences industry will go toward reversing the slowdown in clinical trial uptake. |
By Max Bayer Former Arena CEO Munshi will lead new RNA-focused biotech. Larkspur launches with an all-woman leadership team. CytoDyn finds itself with another executive hole to fill. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Andrea Park Activist investor Carl Icahn’s proxy battle against Illumina reached its conclusion Thursday with wins and losses on both sides. |
By Angus Liu Keytruda’s first-in-class FDA approval as a first-line therapy in metastatic cervical cancer arrived in 2021 with a restriction. Now, researchers say new patient survival data suggest the Merck drug could be used in a broader patient population. |
By Angus Liu Bristol Myers Squibb's Breyanzi is the first CAR-T drug to deliver a positive readout in chronic lymphocytic leukemia in a pivotal multicenter study. But the study's small size and its single-arm nature might raise uncertainties for drug regulators. |
By Teresa Carey This week on "The Top Line," we discuss the 20 most influential people in biopharma, plus a topical gene therapy, a new opioid overdose medication, and the rest of the week's headlines. |
By Angus Liu J&J and Legend Biotech filed to move Carvykti up the treatment line in Europe. Thermo Fisher opened a new facility in Singapore. Celltrion's Humira biosimilar won an FDA approval after a manufacturing problem delayed the review. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the history of 'food is medicine' and where the movement has room to grow. We also talk about our special report comparing top-paid health system execs with payer execs. |
|
|---|
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
